Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Six-month trial results show Lumigan clinically superior to timolol in lowering IOP

March 6, 2001

Japanese patent issued to Santen for new agents for glaucoma

March 1, 2001

Statistically significant phase II results reported for INS-365 Ophthalmic

Feb. 28, 2001

Santen granted rights to develop and market lomerizine for ophthalmological indications

Feb. 27, 2001

Promising data reported for Visudyne in occult AMD and pathological myopia

Feb. 14, 2001

GenVec to apply PEDF technology to the treatment of blindness

Feb. 13, 2001

FDA issues approvable letter for Visudyne

Feb. 5, 2001

Clearance sought to begin clinical trials with INS-37217 Ophthalmic

Feb. 2, 2001

Clinical evaluation of Envision TD for DME and posterior uveitis continues

Jan. 26, 2001

New ROCK inhibitor with potential for the treatment of glaucoma licensed out by Welfide

Jan. 25, 2001

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....